Jian Jenny Chen

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Venues

Communications medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R Patel, Dejan Juric, Patrick Y Wen, Andrea J Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S Watnick, Michael Cieslewicz, Jing Watnick
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. Communications medicine 4 (1) (2024)
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R Patel, Dejan Juric, Patrick Y Wen, Andrea J Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S Watnick, Michael Cieslewicz, Jing Watnick
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. Communications medicine 4 (1) (2024)
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea J Bullock, Randolph S Watnick, Melanie Y Vincent, Jian Jenny Chen, Suming Wang, Harold Pestana, Judy Chao, James Mahoney, Michael Cieslewicz, Jing Watnick
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors. Communications medicine 4 (1) (2024)
Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea J Bullock, Randolph S Watnick, Melanie Y Vincent, Jian Jenny Chen, Suming Wang, Harold Pestana, Judy Chao, James Mahoney, Michael Cieslewicz, Jing Watnick
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors. Communications medicine 4 (1) (2024)
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, David Peereboom, Devalingam Mahalingam, James Battiste, Manish R Patel, Dejan Juric, Patrick Y Wen, Andrea J Bullock, Jennifer Eva Selfridge, Shubham Pant, Joyce Liu, Wendy Li, Susanne Fyfe, Suming Wang, Victor Zota, James Mahoney, Randolph S Watnick, Michael Cieslewicz, Jing Watnick
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors. Communications medicine 4 (1) (2024)

Jian Jenny Chen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jian Jenny Chen